News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

“Lung Cancer Talk”: A Review of Data from the ASCO 2020 Virtual Meeting

EP. 1: RET Fusion+ mNSCLC

ByJoshua M. Bauml, MD, Perelman School of Medicine,Hossein Borghaei, DO, MS, Fox Chase Center at Temple Health,Balazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins

September 1st 2020

EP. 2: MET Exon 14 Mutations in mNSCLC

ByJoshua M. Bauml, MD, Perelman School of Medicine,Hossein Borghaei, DO, MS, Fox Chase Center at Temple Health,Balazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins

September 1st 2020

EP. 3: HER2 Targeted Therapy for Treatment of NSCLC

ByJoshua M. Bauml, MD, Perelman School of Medicine,Hossein Borghaei, DO, MS, Fox Chase Center at Temple Health,Balazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins

September 1st 2020

EP. 4: KRAS-Mutant NSCLC

ByJoshua M. Bauml, MD, Perelman School of Medicine,Hossein Borghaei, DO, MS, Fox Chase Center at Temple Health,Balazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins

September 1st 2020

EP. 5: EGFR Exon 20 Mutations in NSCLC

ByJoshua M. Bauml, MD, Perelman School of Medicine,Hossein Borghaei, DO, MS, Fox Chase Center at Temple Health,Balazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins

September 1st 2020

EP. 6: Updates on I/O Therapy for Non-Driver mNSCLC

ByJoshua M. Bauml, MD, Perelman School of Medicine,Hossein Borghaei, DO, MS, Fox Chase Center at Temple Health,Balazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins

September 1st 2020

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies